Linden Thomas Advisory Services LLC Invests $186,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Linden Thomas Advisory Services LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 11,077 shares of the biopharmaceutical company’s stock, valued at approximately $186,000.

A number of other hedge funds and other institutional investors have also modified their holdings of CPRX. SG Americas Securities LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth about $502,000. Exchange Traded Concepts LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth about $365,000. Handelsbanken Fonder AB grew its holdings in shares of Catalyst Pharmaceuticals by 92.3% during the third quarter. Handelsbanken Fonder AB now owns 27,877 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 13,377 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Catalyst Pharmaceuticals by 25.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,692 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 5,044 shares during the last quarter. Finally, Assetmark Inc. lifted its position in Catalyst Pharmaceuticals by 11.1% during the third quarter. Assetmark Inc. now owns 62,173 shares of the biopharmaceutical company’s stock valued at $727,000 after buying an additional 6,218 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $14.89 on Friday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $11.09 and a twelve month high of $17.76. The firm’s 50 day moving average price is $15.52 and its two-hundred day moving average price is $14.61. The firm has a market cap of $1.76 billion, a PE ratio of 24.41, a P/E/G ratio of 0.81 and a beta of 0.89.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.45 by $0.04. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. The company had revenue of $110.57 million for the quarter, compared to analyst estimates of $105.78 million. Equities analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CPRX has been the topic of a number of recent research reports. StockNews.com raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Cantor Fitzgerald reissued an “overweight” rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. HC Wainwright reissued a “buy” rating and set a $24.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, March 1st. Bank of America began coverage on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They issued a “buy” rating and a $23.00 target price for the company. Finally, TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $26.43.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total transaction of $411,000.00. Following the transaction, the insider now directly owns 124,433 shares of the company’s stock, valued at $2,045,678.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 12.10% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.